BioSpace News Archive

Miravo Healthcare ™ Announces Fourth Quarter 2021 Results Release Date and Conference Call Details.

Enzolytics, Inc. today announced its progress toward the production and use of its ITV-1, anti-HIV immunotherapy treatment in the Central and Eastern regions of Africa for patients with HIV/AIDS.

Deborah Heart and Lung Center announces its successful hospital-wide go live with Ivenix, a modern smart infusion pump system.

Biosystems GmbH, active in the development of multiplex protein analysis assays for drug discovery and translational research, today announced the successful closing of a financing round which will provide runway for the coming 3 - 5 years.

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, announced the appointment of Carolyn Finkle as senior vice president, head of regulatory affairs.

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced data demonstrating that Reachable Workspace (RWS) is a quantitative and relevant measurement of function that can be used to assess disease progression as well as response to treatment in people with facioscapulohumeral muscular dystrophy (FSHD).

Avadel Pharmaceuticals plc announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 17, 2022, to provide a corporate update and discuss the Company’s financial results for the fourth quarter and full year ended December 31, 2021.

Heat Biologics, Inc., a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, provided strategic, financial, and operational updates for the year ended December 31, 2021.

Kamada Ltd., a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announced the appointments of two executives to its U.S. leadership team.

Agile Therapeutics, Inc. announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to sell 2,425 shares of Series A convertible preferred stock and 2,425 shares of Series B convertible preferred stock and Series A warrants to purchase up to an aggregate of 24,250,000 shares of common stock and Series B warrants to purchase up to an aggregate of 24,250,000 shares of common stock.